Valeurs | |||||
Le rangement donne un aperçu de toutes les valeurs mobilières classées de manière alphabétique ou selon les indices. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Nom | Code | Analysis date | Cours de clôture | +/- % |
Accelerate Diagnostics | AXDX | 17. avr 2025 | 0.55 | -1.81 |
Accenture A | ACN | 17. avr 2025 | 282.35 | -1.01 |
ACCESS Newswire | ACCS | 17. avr 2025 | 8.40 | 0.00 |
Acco Brands | ACCO | 17. avr 2025 | 3.61 | +0.28 |
Accolade | ACCD | 17. avr 2025 | 7.02 | 0.00 |
Accuray | ARAY | 17. avr 2025 | 1.48 | +1.37 |
Acelyrin | SLRN | 17. avr 2025 | 2.20 | 0.00 |
Achieve Life Sciences | ACHV | 17. avr 2025 | 1.99 | -5.69 |
ACI Worldwide | ACIW | 17. avr 2025 | 50.94 | -0.72 |
Aclarion | ACON | 17. avr 2025 | 8.98 | -1.32 |
Aclaris Therapeutics | ACRS | 17. avr 2025 | 1.14 | +0.89 |
ACM Research A | ACMR | 17. avr 2025 | 19.36 | -1.88 |
Acme United | ACU | 17. avr 2025 | 41.38 | +3.24 |
ACNB | ACNB | 17. avr 2025 | 40.63 | +0.69 |
ACRES Commercial Realty | ACR | 17. avr 2025 | 17.15 | -2.33 |
ACRES Commercial Realty C Pref | ACR-C | 17. avr 2025 | 23.85 | +0.21 |
ACRES Commercial Realty D Pref | ACR-D | 17. avr 2025 | 19.50 | +0.10 |
Acrivon Therapeutics | ACRV | 17. avr 2025 | 1.81 | -2.16 |
Actelis Networks | ASNS | 17. avr 2025 | 0.65 | +2.70 |
Actinium Pharmaceuticals | ATNM | 17. avr 2025 | 1.21 | -3.20 |
Active Bear ETF | HDGE | 17. avr 2025 | 19.29 | -1.13 |
Active U.S. Real Estate Powershares | PSR | 17. avr 2025 | 89.33 | +1.42 |
Actuate Therapeutics | ACTU | 17. avr 2025 | 8.00 | -2.79 |
Acuity | AYI | 17. avr 2025 | 229.02 | +0.21 |
Acumen Pharmaceuticals | ABOS | 17. avr 2025 | 0.90 | -8.08 |
Acuren | TIC | 17. avr 2025 | 9.70 | 0.00 |
Acurx Pharmaceuticals | ACXP | 17. avr 2025 | 0.37 | -3.19 |
Acushnet | GOLF | 17. avr 2025 | 59.72 | +0.73 |
ACV Auctions | ACVA | 17. avr 2025 | 14.31 | +1.56 |
ACWI Ex-US Index MSCI Ishares | ACWX | 17. avr 2025 | 54.65 | +0.96 |
|
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.